Levetiracetam XR in Very Heavy Drinkers

Completed · Phase 2

Conditions studied: Alcoholism

In brief

The primary objectives of this study are to assess the efficacy of levetiracetam XR in increasing the percentage of subjects with no heavy drinking days and in reducing the weekly percentage of heavy drinking days in subjects with alcohol dependence confirmed by DSM-IV criteria and who frequently consume 10 or more drinks per drinking day for men and 8 or more drinks per drinking day for women (designated as "very heavy" drinkers).

Key facts

Study ID

NCT00970814

Run by

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

People needed

130

Starts

2009-10-01

Expected to finish

2010-10-01

Last updated by the study team

2014-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The subject must be at least 18 years of age.
• The subject must have a DSM-IV diagnosis of current alcohol dependence.
• The subject must be seeking treatment for alcohol dependence and desires a reduction or cessation of drinking.
• The subject must be able to verbalize understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
• If the subject is female and of child bearing potential, she must agree to use at least one of the following methods of birth control, or she must be surgically sterile or postmenopausal:
• oral contraceptives
• contraceptive sponge
• patch
• barrier (diaphragm or condom)
• intrauterine contraceptive system
• levonorgestrel implant
• medroxyprogesterone acetate contraceptive injection
• complete abstinence from sexual intercourse, and/or
• hormonal vaginal contraceptive ring.
• The subject must be able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits.
• The subject must complete all psychological assessments required at screening and baseline.
• The subject must provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.
• The subject must have a breath alcohol concentration (BAC) equal to 0.000 when s/he signed the informed consent document.

Where it is running

• Johns Hopkins School of Medicine — Baltimore, Maryland, United States
• Boston University School of Medicine — Boston, Massachusetts, United States
• Dartmouth Medical School — Lebanon, New Hampshire, United States
• University Of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.